Biohaven Class Action Lawsuit Filed Over Securities Violations.
ByAinvest
Saturday, Aug 16, 2025 10:51 am ET1min read
BHVN--
The class action, docketed under 25-cv-01120, is on behalf of all persons and entities that purchased or otherwise acquired Biohaven securities during the specified period. The complaint alleges that throughout this period, the defendants made materially false and misleading statements about the company's business, operations, and prospects, and failed to disclose significant adverse information [1].
Key allegations include the overstatement of troriluzole's regulatory prospects as a treatment for spinocerebellar ataxia (SCA), the sufficiency of data submitted for regulatory approval, and the efficacy of BHV-7000 for the treatment of bipolar disorder. These misrepresentations are alleged to have had a significant negative impact on Biohaven's business and financial condition [1].
Investors who purchased Biohaven securities during the class period are urged to contact Pomerantz LLP to discuss their potential eligibility to join the class action. The deadline to ask the court to appoint a lead plaintiff is September 12, 2025 [1].
References:
[1] Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN. (2025). PR Newswire. Retrieved from https://www.morningstar.com/news/pr-newswire/20250816dc48907/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-biohaven-ltd-and-certain-officers-bhvn
Pomerantz LLP has filed a class-action lawsuit against Biohaven Ltd. and certain officers, alleging violations of federal securities laws. The lawsuit, filed in the US District Court for the District of Connecticut, seeks damages for investors who purchased Biohaven securities between March 24, 2023 and May 14, 2025. The deadline for investors to ask the court to appoint them as lead plaintiff is September 12, 2025.
New York, Aug. 16, 2025 - Pomerantz LLP has announced the filing of a class action lawsuit against Biohaven Ltd. and certain officers, alleging violations of federal securities laws. The lawsuit, filed in the US District Court for the District of Connecticut, seeks damages for investors who purchased Biohaven securities between March 24, 2023 and May 14, 2025 [1].The class action, docketed under 25-cv-01120, is on behalf of all persons and entities that purchased or otherwise acquired Biohaven securities during the specified period. The complaint alleges that throughout this period, the defendants made materially false and misleading statements about the company's business, operations, and prospects, and failed to disclose significant adverse information [1].
Key allegations include the overstatement of troriluzole's regulatory prospects as a treatment for spinocerebellar ataxia (SCA), the sufficiency of data submitted for regulatory approval, and the efficacy of BHV-7000 for the treatment of bipolar disorder. These misrepresentations are alleged to have had a significant negative impact on Biohaven's business and financial condition [1].
Investors who purchased Biohaven securities during the class period are urged to contact Pomerantz LLP to discuss their potential eligibility to join the class action. The deadline to ask the court to appoint a lead plaintiff is September 12, 2025 [1].
References:
[1] Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN. (2025). PR Newswire. Retrieved from https://www.morningstar.com/news/pr-newswire/20250816dc48907/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-biohaven-ltd-and-certain-officers-bhvn
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet